Some of the promising ones involve transduction of a fusion gene construct of GM-CSF and carbonic anhydrase IX into autologous DCs [NCT01826877] [111], pidilizumab (a PD-1 antibody) in combination with DC/RCC fusion cells [NCT01441765] [112], and DCs in combination with cytokine-induced killer cells [NCT00862303] [113]. The gene discussed is PDCD1; the disease is renal cell carcinoma.